Editorial: safety of ustekinumab in pregnancy-are we there yet?
- PMID: 35092058
- DOI: 10.1111/apt.16767
Editorial: safety of ustekinumab in pregnancy-are we there yet?
Comment on
-
Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.Aliment Pharmacol Ther. 2022 Mar;55(6):700-704. doi: 10.1111/apt.16739. Epub 2021 Dec 14. Aliment Pharmacol Ther. 2022. PMID: 34907546
References
REFERENCES
-
- van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-124.
-
- Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160:1131-1139.
-
- Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228-233.
-
- Flanagan E, Gibson PR, Wright EK, et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52:1551-1562.
-
- Grišić A-M, Dorn-Rasmussen M, Ungar B, et al. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United European Gastroenterol J. 2021;9:91-101.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical